(FM) Patología, Anatomía y Fisiología
Departamento académico
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (25)
2024
-
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
Nature Communications, Vol. 15, Núm. 1
2023
-
Correction to: New update to the guidelines on testing predictive biomarkers in non‑small‑cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2022), 25, 5, (1252-1267), 10.1007/s12094-022-03046-9)
Clinical and Translational Oncology
-
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Nature Communications, Vol. 14, Núm. 1
-
New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia, Vol. 56, Núm. 2, pp. 97-112
-
New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 25, Núm. 5, pp. 1252-1267
-
PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526
-
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution
eLife, Vol. 12
2022
-
Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer
Journal for immunotherapy of cancer, Vol. 10, Núm. 12
-
Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition
European Journal of Cancer, Vol. 174, pp. S47
-
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity
The Journal of experimental medicine, Vol. 219, Núm. 12
-
Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness
Frontiers in Cell and Developmental Biology, Vol. 10
-
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes
Nature Communications, Vol. 13, Núm. 1
2021
-
Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma
Frontiers in Cell and Developmental Biology, Vol. 9
-
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer
Molecular Oncology, Vol. 15, Núm. 4, pp. 887-900
-
The transcription factor SLUG uncouples pancreatic cancer progression from the RAF–MEK1/2–ERK1/2 pathway
Cancer Research, Vol. 81, Núm. 14, pp. 3849-3861
2020
-
Epigenetic SmAd3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma
Cancer Research, Vol. 80, Núm. 2, pp. 276-290
-
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors
Annals of Oncology, Vol. 31, Núm. 2, pp. 274-282
2019
-
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging
Thorax, Vol. 74, Núm. 4, pp. 371-379
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
-
YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib
American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899